About
At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Our commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with early-stage programs that address other unmet patient needs.
Focus
Life Sciences
Lease
Markets
FAQs
Acadia Pharmaceuticals has financed 1 deal.
Acadia Pharmaceuticals's most recent deal was on November 01, 2025.
Member since: November 2025
Deals
Transaction Type
Asset Type
State
Sort By
LEASED
Catherine Owen Adams Of Acadia Pharmaceuticals Leases 16000 SF At Kilroy Realty's Oyster Point Campus
384 Oyster Point Boulevard, South San Francisco, CA
CACRE
Nov 1, 2025